Coherus Oncology (CHRS) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 68.1% versus a loss of 76.7%. Over five years, CHRS leads with a -98.0% price change compared with -98.5% for TNYA. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $57.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | TNYA |
|---|---|---|
| Share price | $0.3698 | $0.2866 |
| Market cap | $57.15M | $65.32M |
| 1-day change | -4.47% | -3.99% |
| YTD return | -73.96% | -59.75% |
| 1-year return | -68.12% | -76.70% |
| 5-year return | -97.99% | -98.50% |
| EPS (TTM) | $-1.12 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.17M | — |
| Revenue growth (YoY) | +59.81% | — |
| Net income (latest FY) | $168.02M | $-90.60M |
| Gross margin | 67.24% | — |
| Operating margin | -429.51% | — |
| Net margin | 398.43% | — |
| 52-week high | $2.62 | $1.46 |
| 52-week low | $0.3628 | $0.28 |
| Distance from 52-week high | -85.86% | -80.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1995.73% | +1016.54% |
| Average volume | 1.80M | 2.96M |
| Shares outstanding | 154.54M | 227.93M |
| Employees | 144 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
CHRS vs TNYA FAQ
Which is bigger, Coherus Oncology or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $57.15M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or TNYA?
CHRS returned -68.12% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.